,,ii #aaeth ,,congress #b;d ,session ,s4 #cefe ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,october #aj1 #bjah ,mrs4 ,mc,caskill 7for herself and ,mr4 ,cassidy7 introduced the following bill2 which was read twice and referred to the ,committee on ,finance ,a ,,bill ,to amend title ,,xi of the ,social ,security ,act to include additional covered recipients for transparency reports required of manufacturers of opioids4 #a4 ,short title ,this ,act may be cited as the ,opioid ,advocacy ,transparency ,act of #bjah4 #b4 ,additional covered recipients for transparency reports required of manufacturers of opioids 7a7 ,in general ,section #aabh;,g7e7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;h7e77 is amended-- 7#a7 in paragraph 7#f7-- 7,a7 in subparagraph 7,a7-- 7i7 in the matter preceding clause 7i71 by inserting and subject to subparagraph 7,c7 after subparagraph 7,b72 and 7ii7 by adding at the end the following new clause3 7vi7 ,a relevant patient advocacy organization 7as defined in subparagraph 7,d77 or a foundation established by such an organization4 2 and 7,b7 by adding at the end the following new subparagraphs3 7,c7 ,limitation ,clause 7vi7 of subparagraph 7,a7 shall only apply with respect to information required to be submitted under this section by an applicable manufacturer that is the manufacturer of a covered drug1 device1 biological1 or medical supply that is an opioid 7as defined in section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb774 7,d7 ,relevant patient advocacy organization ,for purposes of subparagraph 7,a77vi71 the term relevant patient advocacy organization means an organization engaged in advocacy on issues related to opioids 7as so defined71 including patient use of and access to opioids1 the use of opioids for the treatment of pain1 and opioid addiction treatment4 2 and 7#b7 in paragraph 7#aj77;,b7-- 7,a7 in clause 7i71 by striking ,a transfer and inserting ,subject to clause 7xiii71 a transfer2 and 7,b7 by adding at the end the following new clause3 7xiii7 ,in the case of a covered recipient described in paragraph 7#f77;,a77vi71 a transfer of anything of value to the covered recipient by an applicable manufacturer described in paragraph 7#f77;,c71 unless the aggregate amount transferred to1 requested by1 or designated on behalf of the covered recipient by the applicable manufacturer during the calendar year exceeds #d1jjj4 ,for calendar years after #bjbd1 the dollar amount specified in the preceding sentence shall be increased by the same percentage as the percentage increase in the consumer price index for all urban consumers 7all items2 ,u4,s4 city average7 for the #ab-month period ending with ,june of the previous year4 4 7b7 ,treatment of certain payments or other transfers of value made by pharmaceutical trade associations ,section #aabh;,g7a77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;h7a77#a77 is amended by adding at the end the following new subparagraph3 7,c7 ,treatment of certain payments or other transfers of value by pharmaceutical trade associations ,for purposes of this section1 the provisions that apply to an applicable manufacturer with respect to a payment or other transfer of value described in subparagraph 7,a7 shall also apply to a pharmaceutical trade organization 7as defined by the ,secretary7 but only with respect to a payment or other transfer of value described in such subparagraph provided to a covered recipient described in subsection 7e77#f77;,a77vi7 7or to an entity or individual at the request of or designated on behalf of a covered recipient described in such subsection74 4 7c7 ,effective date ,the amendments made by this section shall apply with respect to information required to be submitted under section #aabh;,g of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;h7 on or after ,january #a1 #bjbd4